<DOC>
	<DOCNO>NCT01793480</DOCNO>
	<brief_summary>This multicentric , randomize , open-label , phase IIIb national study , evaluate clinical effect ( success/failure ) methadone treatment cancer-related-pain patient inadequate pain relief intolerable side effect treat level 3 opioid . Principal objective compare clinical effect ( success/failure ) two method methadone titration patient cancer-related pain inadequately relieve intolerable side effect treatment level 3 opioid . Secondary objective : Overall safety methadone study , describe patient ' characteristic , describe effect methadone pain relief , describe methadone administration , evaluate patient 's quality life , evaluate prescriber 's opinion regard handle methadone initiation .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Two Methadone Titration Methods Treatment Cancer-related Pain With Inadequate Pain Relief Intolerable Side Effects When Treated With Level 3 Opioids .</brief_title>
	<detailed_description>The randomisation ( 1:1 ) consider two titration methadone switch method : - Group A : patient-controlled dose methadone overlap previous opioid treatment - Group B : fixed-dose methadone overlap previous opioid treatment Study Description : Screening visit ( Visit 1 ) within 48 hour inclusion Inclusion visit ( Visit2 ) randomisation Day 1 Visit 3 Day 2 Day 7 ( hospitalisation patient ) . Four follow-up visit Day 14 ( Visit 4 ) , Day 21 ( Visit 5 ) , Day 28 ( Visit 6 ) , Day 42 ( Visit 7 ) End study visit Day 56 Follow-up phone contact Day 84 .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Adult patient least 18 year age Patient suffer cancer disease , undergo chemotherapy treatment , hospitalise require hospitalisation Patient present nociceptive mixed pain inadequately relieve level 3 opioids ( morphine , oxycodone , transdermal fentanyl , hydromorphone ) numeric pain scale score â‰¥5 evidencebased present intolerable side effect level 3 opioids Patient undergoing level 3 opioid treatment ( morphine sulphate morphine chlorhydrate fentanyl oxycodone hydromorphone ) Patient present good understanding study objective able give his/her write consent Patient able communicate investigator representative Patient available whole course study agree study requirement Patient Social Insurance Patient receive patient 's information form , orally inform sign consent form Patient terminal cancer disease ( life expectancy le 2 month ) accord investigator 's judgement Patient treat medication may result interaction methadone , : antiarrythmic treatment ( Ia III ) , erythromycin , spiramycin , intravenous vincamin Patient receive opioid treatment reason pain Patient unable swallow study treatment Patient present contraindication use methadone Patient decompensated respiratory failure severe hepatic disease Patient know hypersensitivity methadone Patient present QT interval prolongation ECG result Patient receive concomitant treatment morphinetype agonistantagonist medication ( pentazocine , buprenorphine , nalbuphine ) sultopride , morphinic antagonist ( naltrexone ) Patient treat analgesic radiotherapy within 15 day inclusion Patient participate participate another clinical trial new therapy within one month inclusion Patient history substance abuse For woman childbearing potential : pregnancy breastfeeding . Forfeiture freedom guardianship Past history suicidal attempt Patient likely respect study condition and/or study discontinuation criterion accord investigator 's judgement Patient present medical condition illness clinically significant abnormal finding physical examination screening , opinion Investigator , make patient unsuitable study put patient additional risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Methadone cancer pain</keyword>
</DOC>